Rallybio
RLYB
54 hedge funds and large institutions have $76.1M invested in Rallybio in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 12 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
0.22% more ownership
Funds ownership: 10.32% → 10.54% (+0.22%)
7% less funds holding
Funds holding: 58 → 54 (-4)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
28% less capital invested
Capital invested by funds: $105M → $76.1M (-$29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$5.28M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.07M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$562K |
| 4 |
Morgan Stanley
New York
|
+$557K |
| 5 |
BlackRock
New York
|
+$380K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.17M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.28M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.27M |
| 4 |
VA
VR Adviser
New York
|
-$905K |
| 5 |
FSA
Financial Security Advisor
Virginia Beach,
Virginia
|
-$169K |
RLYB Hedge Fund Activity: Q4 2023 in Review
54 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q4 2023, worth a combined $76.1M — down 28% from $105M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RLYB and 9 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 19 added.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $5.28M. The largest seller was Fidelity Investments, cutting an estimated $2.17M.
- 54 institutional investors held Rallybio (RLYB) as of Q4 2023, down from 58 in Q3 2023.
- Funds reported $76.1M of Rallybio stock for Q4 2023, down 28% quarter-over-quarter.
- 9 funds opened new Rallybio positions in Q4 2023 and 12 closed out, a net change of -3 holders.
- The largest Rallybio buyer in Q4 2023 was Aberdeen Group, an estimated $5.28M added.
- The largest Rallybio seller in Q4 2023 was Fidelity Investments, an estimated $2.17M sold.
Based on aggregated 13F filings for Q4 2023.